Abstract: The taste of orally administered drugs is masked by coating the drug with a polymeric membrane which is soluble only at a pH of 5 or more. An acid substance is included in the formulation containing the coated drug to reduce or prevent the dissolution of the membrane in the oral cavity.

Abstract: A pranoprofen-containing, suspending medicinal composition is formed of the following three ingredients (a) to (c):(a) pranoprofen;(b) a suspending agent comprising microcrystalline cellulose-sodium carboxymethylcellulose, sodium carboxymethylcellulose and hydroxypropyl methylcellulose; and(c) a saccharide solution.

Abstract: This invention describes pharmaceutical compositions and methods of treating ulcerating diseases of the gastrointestinal tract in mammals with an acid-resistant fibroblast growth factor compositions. Also described is the use of acid-resistant fibroblast growth factor compositions in the treatment of various other fibroblast growth factor-responsive conditions.

Abstract: The present invention provides for a stabilized solution containing a halogen containing compound which is effective as a sterilizing or disinfecting agent, and a stabilizing agent which suppresses the chemical dissociation of the halogen compound such that the sterilizing capability of the solution is maintained for extended periods of time relative to the solution without the stabilizing agent. The halogen containing compound is selected from the group consisting of chlorine dioxide, bromine oxide, bromine chloride, monochloroamine, bromic acid, iodine monochloride, iodine trichloride and iodine monobromide. The stabilizing agent is a compound having at least one accessible sulphur containing group selected from the group consisting of cyclamic acid, dimethyl sulphoxide, glyoxyl sodium bisulphite, potassium sorbate, sodium cyclamate, sodium metabisulphite, sodium oxalate, sodium sulphite, sodium thiosulphate and thioacetamide.

Abstract: A method of making a stabilized aerosol drug formulation is disclosed, along with the formulations so produced and metered drug inhalers containing the same. The method comprises combining a solid particulate drug composition with a fluoropolymer in a liquid fluorocarbon aerosol propellant to form a stable suspension. Further stabilization can be achieved by cooling the suspension for a time and to a temperature sufficient to adsorb the fluoropolymer to the solid particulate drug composition in the liquid fluorocarbon aerosol propellant. Preferred propellants for carrying out the invention are 1,1,1,2-tetrafluoroethane, heptafluoropropane, and mixtures thereof, and preferred fluoropolymers for carrying out the invention are fluoropolyethers.

Abstract: A suspendible composition comprising a tricyclic compound such as FK 506 substance which is 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylviny 1]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1 .0.sup.4,9 ]octacos-18-ene-2,3,10,16-tetraone, or the like, and a pharmaceutically acceptable surfactant, which can be used as an orally administrable agent or eye drops and is useful for treating various diseases.

Abstract: A pharmaceutical dosage form comprising an HMG-CoA reductase inhibitor compound, e.g., fluvastatin sodium, is disclosed which is stabilized against pH-related degradation by an alkaline stabilizing medium capable of imparting a pH of at least 8 to an aqueous solution or dispersion of the composition.

Abstract: There is disclosed a stable formulation of enalapril salt of the formula I ##STR1## which is prepared in such manner that a compound of formula II ##STR2## is suspended in demineralized water and a stoichiometric amount of the corresponding sodium compound such as sodium carbonate, sodium hydrogen carbonate or sodium hydroxide is added thereto, to this enalapril sodium salt prepared in situ of the formula I ##STR3## formulating additives are added, the whole is homogenized and formulated.

Abstract: The invention discloses an aqueous granulating solution containing sodium, potassium or mixed sodium potassium salt of an edible organic acid selected from the group consisting of citric, malic, tartaric and fumaric acid and optionally containing sodium or potassium bicarbonate. The granulating solution is especially useful for granulating finely divided solids including acetaminophen, ketoprofen or calcium carbonate. The resulting granulate may be used to prepare a swallow tablet or mixed with an edible organic acid and the mixture tableted to provide an effervescent tablet without resorting to controlled reaction or special handling techniques.

Abstract: Medicinal compositions containing fibroblast growth factor are stabilized against loss of biological activity by including in said composition a stabilizing amount of phytic add, phosvitin, phosphate buffer, (NH.sub.4).sub.6 P.sub.4 O.sub.13, Na.sub.5 P.sub.3 O.sub.10, Na.sub.4 P.sub.2 O.sub.7 and Na.sub.3 P.sub.3 O.sub.9, adenosine tetra, tri, di and mono phosphate and related diadenosine compounds plus other single and multi-phosphorylated mono and di-nucleotides, poly-aspartic acid, poly-adenylic-guanylic add and related compounds, double stranded deoxyribonucleic add, single stranded deoxyfibonucleic acid and poly-glutamic acid. Medicinal compositions for topical use are combined with a viscous excipient such as a water soluble polysaccharide with said combination with a second stabilizier.

Abstract: This invention discloses a composition comprised of nanoparticles having a surface modifier adsorbed on the surface thereof and a non-ionic cloud point modifier associated therewith, which cloud point modifier is present in an amount-sufficient to increase the cloud point of the surface modifier. A preferred surface modifier is a poloxamine such as Tetronic 908, and preferred non-ionic cloud point modifiers include polyethylene glycol, propylene glycol, ethanol, hydroxypropylcyclodextrin and/or glycerol. This invention further discloses a method of making nanoparticles having a surface modifier adsorbed on the surface and a non-ionic cloud point modifier associated therewith, comprised of contacting said nanoparticles with the cloud point modifier for a time and under conditions sufficient to increase the cloud point of the surface modifier.

Abstract: Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2 -Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight mono- or poly-oxy-alkane diol, e.g. Transcutol or Glycofurol, as hydrophilic component. Compositions are also provided comprising a cyclosporin and (1.1) and, suitably, also a saccharide monoester, e.g. raffinose or saccharose monolaurate. Dosage forms include topical formulations and, in particular, oral dosage forms.

Abstract: A W/O skin cream preparation for external use useful as a remedy for skin diseases which consists of a cream base comprising a diglycerol fatty acid ester and/or a sorbitan fatty acid ester having an HLB value of from 3 to 7, a polyvalent metal salt of a saturated or unsaturated fatty acid having 10 to 22 carbon atoms, an inorganic or organic acid salt, an oily phase component, and water together with an active ingredient.

Abstract: Fibroblast growth factor (FGF) or a mutein of FGF is stabilized by bringing FGF or a mutein of FGF into contact with a glucan sulfate in an aqueous medium. Thus obtained composition comprising (a) FGF or a mutein of FGF and (b) a glucan sulfate is stabilized, so that it can be advantageously administered to warm-blooded animals.

Abstract: A method for treating corneal endothelial wounds comprises administering TGF-.alpha. to the region of the wound in an amount sufficient to promote the healing of endothelial cells.TGF-.alpha. advantageously is administered into the anterior chamber during ophthalmic surgical procedures, such as during intra-ocular lens implantation. The TGF-.alpha. preferably is administered as an active ingredient in an ophthalmological viscoelastic composition which improves the residence time of the growth factor in the anterior chamber.

Abstract: A teat dip composition useful for the treatment of mastitis in dairy cows. The composition in application form is in the form of an oil-in-water emulsion. The oil phase includes an unsaturated fatty acid, for example linseed oil fatty acid, having a carbon chan length in the range of C16 to C20.

Abstract: A polyprenyl compound having formula (1) is stabilized by a tocopherol, an organic acid, a neutral amino acid or a basic amino acid: ##STR1## in which n is an integer of 1 to 3.

Abstract: A method of stabilizing aqueous microemulsions against hydrolysis or phase separation of the active ingredient therein comprising buffer the microemulsion to acidic conditions using a surface active hydrophobic acid having a pKa of about 2-5, which have a hydrophobic group capable of entering micelles to preclude an undesired increase in electrolyte strength in the bulk aqueous medium. The method is particularly applicable to active ingredients which ordinarily hydrolyze under basic conditions, or precipitate in an acid medium buffered by conventional inorganic acids. An embodiment of the invention comprises an aqueous microemulsion of a carbamate ester which is stabilized against hydrolysis or precipitation at a pH of about 6.5 with a buffer of nonylphenyl ethoxylated phosphoric acid.

Abstract: This invention relates to a photostabilizing method for ophthalmic solutions and the resulting ophthalmic solutions therefrom. The stabilization is attained by adding polyhydric alcohol and boric acid, and/or sodium borate to ophthalmic solutions which contain a drug substance unstable against light.

Abstract: A method of stabilizing an aqueous microemulsion of a water-insoluble agriculturally active compound to remain clear and free of precipitation after standing for 6 months at a temperature of 2.degree.-3.degree. C. which comprises adding a polyhydric alcohol with at least 3 hydroxyl groups to the microemulsion.

Abstract: The unpleasant taste of water-soluble ibuprofen salts in aqueous solution is masked by incorporating in the solution a taste-masking amount of an alkali metal bicarbonate, alkali metal monohydrogen phosphate or alkali metal tribasic citrate. Preferably, the taste-masking compound is an alkali metal bicarbonate, especially sodium bicarbonate.

Abstract: A method of stabilizing a radiopharmaceutical complex composition is provided comprising the use of an element of Group VII of the Periodic Table selected from technetium, rhenium and manganese, or lanthanum or a transitional metal element or Rare Earth element with Atomic Number of 57 to 71 inclusive that has a range of valency states and an organic complexing compound which is capable of complexing with the radiopharmaceutical element defined above to provide a complex suitable for use in diagnosis and medical treatment, comprising the addition of sufficient of a pharmacologically acceptable weak oxidizing agent to stabilize the radiopharmaceutical complex composition. It is preferred to employ Technetium - 99m as the radiopharmaceutical element, the hemaxmethyl derivative of propyleneamineoxime as the complexing compound and sodium hypochlorite as the weak oxidizing agent. A stabilized composition comprising the same components is also provided.

Abstract: A pharmaceutical solution which contains the compound of the general formula having the immusuppreseive activity is disclosed.

Abstract: A dental composition, such as a paste or gel dentifrice containing triclosan, as an antibacterial agent which acts to decrease plaque on the teeth, and polyphosphate for anti-tartar actions, is packaged in a finger actuatable pump-type plastic dispensing container which is made of or includes a solid polymeric material, such as a polyfluoroethylene, which is compatible with triclosan, so that excessive loss of its anti-plaque activity on storage is avoided, which losses have been noted when various other plastics have been employed as dispensing container component materials. Alternatively, others of such plastic may be employed for dispensing container parts when a stabilizer, such as a terpene, e.g., limonene, is present in the dentifrice.

Abstract: The hardening agent contains a composition comprised of tannic acid and potassium aluminum sulfate in a ratio of tannic acid to potassium aluminum sulfate ranging from 10 to 1 to 1 to 50 and a stabilizing agent extracted from crude drugs of plants containing a phenol, flavon, flavonoid, catechin or a polycarboxylic acid.

Abstract: An antioxidant system is based on at least one basic amino acid and includes at least one tocopherol or a derivative thereof and at least one nonthiolated polypeptide. Preferably the antioxidant system contains from 0.5 to 20 weight percent of a tocopherol or derivative thereof, 0.5 to 50 weight percent of a basic amino acid and 0.5 to 90 weight percent of a nonthiolated polypeptide. This antioxidant system is employed in cosmetic or pharmaceutical compositions.

Abstract: Peptides previously disclosed as useful for preventing HIV from binding to cell binding sites have now been shown to have thymoleptic qualities and to be useful for tretment of psoriasis in patients who lack antibodies against HIV.

Abstract: The invention relates to novel stable aqueous primycin solutions containing 0.5 to 1.75% by mass/volume of primycin sulfate or 2.5 to 9% by mass/volume of a complex of primycin N-methylpyrrolidone and 2 to 15% by mass/volume of pyroglutamic acid, preferably L-pyroglutamic acid or a soluble salt, preferably the sodium salt thereof as calculated for the volume of the solution to be prepared and 40 to 60% by volume of isopropanol as calculated for the volume of the solution to be prepared as well as water in an amount adding up to 100%. The stable, aqueous primycin solutions are topical antibiotics.

Abstract: Cyclosporin analogs containing a MeAla or MeAbu residue at the 6-position of the cyclic undecapeptide have been discovered to sensitize multidrug resistant cells to certain chemotherapeutic agents. These cyclosporin analogs have also been shown to increase the sensitivity of cells already susceptible to the chemotherapeutic agents. In addition, these cyclosporin A analogs lack the nephrotoxic and immunosuppressive activity of cyclosporin A.

Abstract: A stable solid pharmaceutical composition for oral administration comprising dapiprazole or a physiologically acceptable acid salt thereof together with a pharmaceutically acceptable inert excipient and magnesium oxide as a degradation retarding agent is disclosed.

Abstract: A dental composition, such as a paste or gel dentifrice containing triclosan, as an antibacterial agent which acts to decrease plaque on the teeth, is packaged in a hand holdable and squeezable dispensing container which is made of or includes a part or parts of a solid polymeric material, such as a polyfluoroethylene or polyvinyl chloride, which is compatible with triclosan, so that excessive loss of its anti-plaque activity on storage is avoided, which losses have been noted when various other plastics have been employed as dispensing container component materials. Alternatively, other more reactive plastics may be employed for such dispensing container parts when a stabilizer, such as terpene, e.g., limonene, is present in the dentifrice.

Abstract: Chloroisocyanurate compositions for disinfection and sterilization comprise a dichloroisocynurate and at least one alkaline substance selected from the group consisting of magnesium oxide, magnesium hydroxide, calcium hydroxide and sodium carbonate. The chloroisocyanurate compositions can prevent an increase in hydrogen ion concentration often caused by continuous use of dichloroisocyanurates in closed water systems and have excellent stability in a wet state and stability during storage over long periods of time.

Abstract: Improved lyophilizate compositions of ifosfamide comprising urea as the primary excipient and, optionally, mesna, are produced in a modified freeze-drying process to give products with increased heat stability and extended shelf storage life.

Abstract: This invention relates to omeprazole compositions designed for administration in the rectum, wherein said compositions comprise omeprazole, an active ingredient, a mixture of polyethylene glycols having molecular weights 1,000, 1,540, 4,000 and/or 6,000 or a mixture of adeps solidus and sodium laurylsulfate and a soluble, basic amino acid selected from arginine, lysine or histidine.

Abstract: A biologically active composition made up of core particles having diameters of less than about 1000 nanometers which are coated with a layer which is designed to allow attachment of biologically active proteins, peptides or pharmacological agents to the microparticles. When viral protein is attached to the core particles, the result is a viral decoy which accurately mimics the native virus in both size and structure while being entirely devoid of virulent activity due to the microparticle core. Other antigenic proteins or peptides are attached to provide molecules which are useful in raising antibodies or as a diagnostic tool. Further, pharmacological agents are attached to the microparticles to provide pharmaceutical compositions.

Abstract: Pharmaceutical formulations and a method for their preparation are provided. These formulations provide a stabilized basic fibroblast growth factor (bFGF) which is less susceptible to oxidation or metal-induced aggregation by including an amount of a chelating agent effective to stabilize the bFGF.

Abstract: The stability of compositions of choline salicylate-metal salicylate-carboxymethylcellulose is improved by the incorporation therein of microcrystalline cellulose. The microcrystalline cellulose is linked to the remainder of the composition by liquid bridges and is preferably present in an amount of about 2.5-25% by weight. The microcrystalline cellulose enhances the stability of the composition and thereby enhances solid dosage forms thereof such as tablets, capsules, suppositories and granules.

Abstract: Compositions are described that are suitable for formulating cytokines, preferably tumor necrosis factor, that maintain their biological activities over a wide range of temperatures by, among other aspects, decreasing them sensitivity to agitation, and preventing oligomer and particulate matter formation.

Abstract: A malodor-free personal cleansing bar with a low level of zeolite odor-controlling agent. The preferred application is a fragrance-free bar, a scented bar, or the like.

Abstract: The present invention relates to methods of neutralizing or dissipating the electrostatic charge of glutathione so as to render it susceptible to be included in high glutathione content solid dosage forms. Capsules and tablets including high levels of glutathione are also described.

Abstract: Aerosol formulations for use in metered dose inhalers are disclosed which include 1,1,1,2-tetrafluoroethane alone and in combination with other compounds as well as various hydrocarbon blends. The density, vapor pressure, flame extension characteristics, dispersability of medicant, dissolvability of surfactant, respirable fraction, and compatibility elastomer seals for the aerosol formulations have been examined. The aerosol formulations are attractive alternatives to chlorofluorocarbon based aerosols since they do not deplete the ozone layer.

Abstract: A pharmaceutical composition is provided which has excellent stability, when dispersed in water has a pH of at least about 9, and includes a medicament which is sensitive to a low pH environment such as pravastatin, one or more fillers such as lactose and/or microcrystalline cellulose, one or more binders, such as microcrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder), one or more disintegrating agents such as croscarmellose sodium, one or more lubricants such as magnesium stearate and one or more basifying agents such as magnesium oxide.

Abstract: The systemic absorption after intranasal administration of certain drugs, in particular pharmacologically active polypeptides is enhanced in the presence of a phospholipid, such as a phosphatidylcholine (a lecithin), preferably admixed with a vegetable oil.

Abstract: An aqueous folinate solution stable at refrigerator temperature is provided which contains folinate ions, complexed calcium ions, and if desired free calcium ions in a total amount of more than 12 mg/ml, as well as anions of a complexing agent for calcium. This solution is prepared by incorporating the complexing agent therein.

Abstract: A process for stabilizing a composition containing an anionic surfactant by using a cationized xanthan gum, a stabilizer for the composition containing an anionic surfactant which contains a cationized xanthan gum as a component, and a anionic surfactant-containing composition stabilized by inclusion of a cationized xanthan gum.

Abstract: This invention describes pharmaceutical compositions and methods of treating ulcerating diseases of the gastrointestinal tract in mammals with an acid-resistant fibroblast growth factor compositions. Also described is the use of acid-resistant fibroblast growth factor compositions in the treatment of various other fibroblast growth factor-responsive conditions.

Abstract: A pharmaceutical solid preparation of active form of vitamin D.sub.3 of improved stability which comprises a composition of active form of vitamin D.sub.3 dispersed in an excipient readily soluble in organic solvent and a basic substance.As a basic substance, are cited sodium citrate, magnesium oxide or the like.

Abstract: A 5,6,7,8-tetrahydro-1-naphthalenol derivative of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 represent lower alkyl,R.sub.5 and R.sub.6 represent hydrogen or lower alkyl,R represents hydrogen, C.sub.1 -C.sub.18 alkyl, C.sub.2 -C.sub.18 alkyl substituted by one or more hydroxyl groups, C.sub.3 -C.sub.18 alkenyl, C.sub.2 -C.sub.18 acyl, benzyl, benzoyl, carboxyl and carboxylic salts of an alkali or alkaline earth metal or of an organic amine.The derivative is useful as an antioxidant in cosmetic compositions and in pharmaceutical compositions for the preventive treatment of cutaneous inflammations and allergies or certain forms of cancer.

Abstract: A germicidal composition is disclosed which comprises a solvent containing at least 50% by weight of a stabilizing liquid selected from 3-methyl-3-methoxybutyl alcohol and an isothiazolone compound dissolved in the solvent.

Abstract: An injectable composition of nicardipine hydrochloride comprising an aqueous nicardipine hydrochloride solution containing 2-7 w/v % of polyhydric alcohol. This injectable composition can maintain its desired concentration and can be stably stored for a long period of time.